291 related articles for article (PubMed ID: 11087333)
21. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
[TBL] [Abstract][Full Text] [Related]
22. Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies.
Kranenborg MH; Boerman OC; Oosterwijk-Wakka JC; de Weijert MC; Corstens FH; Oosterwijk E
Int J Cancer; 1998 Jan; 75(1):74-80. PubMed ID: 9426693
[TBL] [Abstract][Full Text] [Related]
23. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
24. Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.
Lütje S; Franssen GM; Sharkey RM; Laverman P; Rossi EA; Goldenberg DM; Oyen WJ; Boerman OC; McBride WJ
Bioconjug Chem; 2014 Feb; 25(2):335-41. PubMed ID: 24382090
[TBL] [Abstract][Full Text] [Related]
25. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody.
Rauscher A; Frindel M; Maurel C; Maillasson M; Le Saëc P; Rajerison H; Gestin JF; Barbet J; Faivre-Chauvet A; Mougin-Degraef M
Nucl Med Biol; 2014 May; 41 Suppl():e66-74. PubMed ID: 24485990
[TBL] [Abstract][Full Text] [Related]
26. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
[TBL] [Abstract][Full Text] [Related]
27. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
28. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
29. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
30. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
[TBL] [Abstract][Full Text] [Related]
31. Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes.
van Schaijk FG; Boerman OC; Soede AC; McBride WJ; Goldenberg DM; Corstens FH; Oosterwijk E
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1089-95. PubMed ID: 15902440
[TBL] [Abstract][Full Text] [Related]
32. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
Sharkey RM; Juweid M; Shevitz J; Behr T; Dunn R; Swayne LC; Wong GY; Blumenthal RD; Griffiths GL; Siegel JA
Cancer Res; 1995 Dec; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
[TBL] [Abstract][Full Text] [Related]
34. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
35. High-specific-activity 111In-labeled anticarcinoembryonic antigen monoclonal antibody: biodistribution and imaging in nude mice bearing human colon cancer xenografts.
Jakowatz JG; Beatty BG; Vlahos WG; Porudominsky D; Philben VJ; Williams LE; Paxton RJ; Shively JE; Beatty JD
Cancer Res; 1985 Nov; 45(11 Pt 2):5700-6. PubMed ID: 4053043
[TBL] [Abstract][Full Text] [Related]
36. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
[TBL] [Abstract][Full Text] [Related]
37. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
38. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
Aarts F; Boerman OC; Sharkey RM; Hendriks T; Chang CH; McBride WJ; Bleichrodt RP; Oyen WJ; Goldenberg DM
Cancer; 2010 Feb; 116(4 Suppl):1111-7. PubMed ID: 20127959
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
